Obituaries
PGe
PG Store
Archives
Classifieds
Classified
Events
Jobs
Real Estate
Legal Notices
Pets
MENU
SUBSCRIBE
LOGIN
REGISTER
LOG OUT
MY PROFILE
Home
News
Local
Sports
Opinion
A&E
Life
Business
Contact Us
NEWSLETTERS
MENU
ACCOUNT
Subscribe
Login
Register
Log out
My Profile
Subscriber Services
Search
SECTIONS
HOME
Homepage
This Just In
Chats
Weather
Traffic
Event Guide
PG Store
PGe
Video
Photos
The Digs
RSS Feeds
NEWS
News Home
COVID-19
World
Nation
State
Obituaries
News Obituaries
Politics
Education
Portfolio
Science
Health & Wellness
Environment
Aging Edge
Transportation
Faith & Religion
Crimes & Courts
Social Services
LOCAL
Local Home
Region
City
North
East
West
South
Washington
Westmoreland
The Neighborhood
Obituaries
Classifieds
Legal Notices
Real Estate
SPORTS
Sports Home
Steelers
Penguins
Pirates
Sports Columns
Gene Collier
Ron Cook
Joe Starkey
Paul Zeise
High School Sports
College Sports
Pitt
Penn State
WVU
NCAA
NFL
MLB
NBA
NHL
North Shore Drive Podcast
OPINION
Opinion Home
Editorials
Letters
Op-Ed Columns
PG Columnists
Insight
A&E
A&E Home
Celebrities
Movies
TV & Radio
Music
Concert Listings
Theatre & Dance
Art & Architecture
Books
Events
LIFE
Life Home
Food
Buying Here
Homes & Gardens
Style & Fashion
Travel
Restaurants
Seen
goodness
Random Acts of Kindness
Pets
Beer Me
Outdoors
Holidays
BUSINESS
Business Home
Your Money
Wheels
Workzone
Business Health
Tech News
Building PGH
Powersource
Business / Law
Top Workplaces
Business of Pittsburgh
Consumer Alerts
OTHER
PGe
NEWSLETTERS
PG STORE
ARCHIVES
CLASSIFIEDS
OBITUARIES
JOBS
LEGAL NOTICES
REAL ESTATE
CLASSIFIEDS
EVENTS
PETS
CONTACT US / FAQ
CONTACT US
ADVERTISING
CAREER OPPORTUNITIES
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude+Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Travere Therapeutics, Inc. - Common Stock
(NQ:
TVTX
)
43.49
+1.23 (+2.91%)
Streaming Delayed Price
Updated: 4:00 PM EDT, May 20, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Travere Therapeutics, Inc. - Common Stock
< Previous
1
2
3
4
5
6
7
8
9
...
15
16
Next >
Verrica Pharmaceuticals Reports Quarterly 2025 Financial Results
May 13, 2025
From
Verrica Pharmaceuticals Inc.
Via
GlobeNewswire
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
May 12, 2025
From
Travere Therapeutics, Inc.
Via
Business Wire
Travere Therapeutics to Participate at Upcoming Investor Conferences
May 07, 2025
From
Travere Therapeutics, Inc.
Via
Business Wire
Earnings Scheduled For May 1, 2025
↗
May 01, 2025
Via
Benzinga
Travere Therapeutics's Earnings: A Preview
↗
April 30, 2025
Via
Benzinga
Analyst Expectations For Travere Therapeutics's Future
↗
February 24, 2025
Via
Benzinga
Earnings Scheduled For February 20, 2025
↗
February 20, 2025
Via
Benzinga
Is TRAVERE THERAPEUTICS INC (NASDAQ:TVTX) following the Minervini trend for explosive growth?
↗
May 02, 2025
Should you consider TRAVERE THERAPEUTICS INC (NASDAQ:TVTX) for high growth investing? A fundamental and technical analysis of (NASDAQ:TVTX).
Via
Chartmill
Travere Therapeutics Reports First Quarter 2025 Financial Results
May 01, 2025
From
Travere Therapeutics, Inc.
Via
Business Wire
Travere Therapeutics and CSL Vifor Announce Standard EU Approval of FILSPARI® (sparsentan) for IgA Nephropathy
April 29, 2025
From
Travere Therapeutics, Inc.
Via
Business Wire
Travere Therapeutics to Report First Quarter 2025 Financial Results
April 24, 2025
From
Travere Therapeutics, Inc.
Via
Business Wire
Assessing Travere Therapeutics: Insights From 8 Financial Analysts
↗
April 23, 2025
Via
Benzinga
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
April 11, 2025
From
Travere Therapeutics, Inc.
Via
Business Wire
Novartis Pops — Hammering Rival Travere Therapeutics — On Its Kidney Drug Approval
↗
April 03, 2025
The companies are going head to head in kidney disease. Here's why Novartis could have a slight advantage.
Via
Investor's Business Daily
The Analyst Verdict: Travere Therapeutics In The Eyes Of 7 Experts
↗
April 01, 2025
Via
Benzinga
Ulta Beauty To Rally Over 15%? Here Are 10 Top Analyst Forecasts For Tuesday
↗
April 01, 2025
Via
Benzinga
Travere Therapeutics to Present New FILSPARI® (sparsentan) Data at the National Kidney Foundation Spring Clinical Meetings 2025
March 31, 2025
From
Travere Therapeutics, Inc.
Via
Business Wire
Travere Therapeutics Submits sNDA to FDA for Approval of FILSPARI® (sparsentan) for the Treatment of FSGS
March 17, 2025
From
Travere Therapeutics, Inc.
Via
GlobeNewswire
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
March 12, 2025
From
Travere Therapeutics, Inc.
Via
GlobeNewswire
Travere Therapeutics to Participate at Upcoming Investor Conferences
February 24, 2025
From
Travere Therapeutics, Inc.
Via
GlobeNewswire
Travere Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results
February 20, 2025
From
Travere Therapeutics, Inc.
Via
GlobeNewswire
Travere Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results
February 13, 2025
From
Travere Therapeutics, Inc.
Via
GlobeNewswire
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
February 12, 2025
From
Travere Therapeutics, Inc.
Via
GlobeNewswire
Travere Therapeutics Sparks Retail Frenzy As Stock Hits Over 2-Year High On FDA Approval Plan For Kidney-Disease Drug
↗
February 11, 2025
The company expects to submit a supplemental New Drug Application (sNDA) based on existing Phase 3 and Phase 2 data by the end of the first quarter.
Via
Stocktwits
Travere Therapeutics Skyrockets After Reaching FDA Deal For Kidney Disease Drug
↗
February 11, 2025
The company is nearing a highly anticipated approval for a kidney disease drug.
Via
Investor's Business Daily
Lattice Semiconductor, SelectQuote, Radiant Logistics And Other Big Stocks Moving Higher On Tuesday
↗
February 11, 2025
Via
Benzinga
Travere Therapeutics to Submit sNDA for FILSPARI® (sparsentan) in FSGS
February 11, 2025
From
Travere Therapeutics, Inc.
Via
GlobeNewswire
Travere Therapeutics Provides Corporate Update and 2025 Outlook
January 13, 2025
From
Travere Therapeutics, Inc.
Via
GlobeNewswire
Biotech Stocks Prepare For Action In 2025. Weight-Loss Drugs, AI And Trump 2.0 Are The Catalysts.
↗
January 09, 2025
Biotech stocks have seen three years of sideways to down trading. But obesity drugs, AI and Trump 2.0 promise to shake things up.
Via
Investor's Business Daily
Topics
Artificial Intelligence
Government
Travere Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference
January 06, 2025
From
Travere Therapeutics, Inc.
Via
GlobeNewswire
< Previous
1
2
3
4
5
6
7
8
9
...
15
16
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story
Your e-mail:
Friends e-mail:
Submit
